Concord Biotech Limited (BOM:543960)

Market Cap	123.91B -40.2%
Revenue (ttm)	11.59B +6.4%
Net Income	3.13B -4.2%
EPS	29.69 -4.8%
Shares Out	n/a
PE Ratio	39.65
Forward PE	30.94
Dividend	10.70 (0.86%)
Ex-Dividend Date	Sep 3, 2025

Volume	6,760
Average Volume	19,557
Open	1,202.20
Previous Close	1,229.00
Day's Range	1,175.50 - 1,218.50
52-Week Range	1,100.00 - 2,183.90
Beta	n/a
RSI	42.48
Earnings Date	Feb 11, 2026

About Concord Biotech

Concord Biotech Limited, a biopharma company, engages in the research and development, manufacture, market, and sale of pharmaceutical products in India and internationally. The company provides fermentation based active pharmaceutical ingredients in immunosuppressants, anti-bacterial, oncology, antifungal, and other therapeutic areas. It also offers tacrolimus, mycophenolate mofetil, mycophenolate sodium, cyclosporine, sirolimus, voclosporin, and pimecrolimus for immunosuppressants therapeutic segment; and temsirolimus, everolimus, romidepsin,...

• Industry: Pharmaceutical Preparations
• Founded: 1984
• Employees: 1,571
• Stock Exchange: Bombay Stock Exchange
• Ticker Symbol: 543960

Financial Performance

In fiscal year 2025, Concord Biotech's revenue was 12.00 billion, an increase of 18.01% compared to the previous year's 10.17 billion. Earnings were 3.72 billion, an increase of 20.62%.